Acceleron Pharma

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Retrieved on: 
Wednesday, November 29, 2023
Research, Legal, Finance, Clinical Trials, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Science, Merck & Co., Acquisition, Ropes & Gray, General counsel, GOSS, Entrepreneurship, Executive, Gossamer, Pulmonary hypertension, Doctor of Philosophy, Bristol Myers Squibb, Orthostatic hypertension, Merck, Stanford University, Harvard College, Acceleron Pharma, Massachusetts Institute of Technology, Harvard Law School, Corporate development, PAH, Biology, Pharmaceutical industry, Management, Acceleron

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors.
  • “Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.
  • We are confident that Dr. Quisel’s appointment enhances our ability to get seralutinib to patients.”
    “I am honored to join Gossamer’s Board at this pivotal moment for the Company,” said Dr. Quisel.
  • During his tenure, Dr. Quisel also served in various roles, including Senior Vice President of Corporate Development and General Counsel.

Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines

Retrieved on: 
Monday, August 21, 2023
Biotechnology, Pharmaceutical, Health, Inflammation, Amgen, Korn Ferry, Johnson & Johnson, Partnership, University, LLM, Sucampo Pharmaceuticals, Woman, MBA, Merrell Dow Pharmaceuticals Inc. v. Thompson, Doctor of Philosophy, Sale, Science, Rutgers University, Organization, Chemistry, Business administration, Nephrology, MD, Janssen Pharmaceuticals, Sangamo Therapeutics, Acceleron Pharma, Growth, Therapy, Family, Management, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors.
  • The selection process included working with Korn Ferry, a global organizational talent firm, to identify and screen multiple qualified candidates.
  • “We are thrilled to have Dr. Smith and Mr. Bailey join Aurinia’s Board of Directors.
  • Both Dr. Smith and Mr. Bailey have served on boards that have had successful outcomes, including sales, mergers, and partnerships.

THE PANCREATIC CANCER ACTION NETWORK (PANCAN) WELCOMES FOUR NEW LEADERS TO ITS DISTIGUISHED BOARD OF DIRECTORS

Retrieved on: 
Tuesday, July 11, 2023
Pancreatic cancer, IBM, Partnership, Gongshi, Drug development, Chair, Life, TD, Physician, COVID-19, American Society of Clinical Oncology, Survival, Accordion, MBA, Research, Oncology, ERP, Accounting, Government, American College of Physicians, Acquisition, Pancreatic Cancer Action Network, Patient, Celgene, JD, Internal medicine, Acceleron Pharma, Growth, Merck, American College, MPH, Hume, Society, Tech Data, TD SYNNEX, Disease, Pharmaceutical industry, Management, Nursing, MD, Pfizer

LOS ANGELES, July 11, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, proudly announces the addition of four esteemed business leaders, Jay T. Backstrom, MD, MPH, Rich Hume, Eric Park and Mace Rothenberg, MD, to its national board of directors. These new additions bring additional expertise to the organization as it takes bold action to accelerate progress for pancreatic cancer patients and create a world in which they thrive. In addition to being leaders professionally and in their communities, all PanCAN's board members understand the impact of pancreatic cancer, giving them a personal interest in advancing PanCAN's mission.

Key Points: 
  • These new additions bring additional expertise to the organization as it takes bold action to accelerate progress for pancreatic cancer patients and create a world in which they thrive.
  • In addition to being leaders professionally and in their communities, all PanCAN's board members understand the impact of pancreatic cancer, giving them a personal interest in advancing PanCAN's mission.
  • Hume lost his wife, Leslie Hume, to pancreatic cancer in 2018 and was her caregiver for the year prior to her passing.
  • "I am excited about PanCAN's investment in research and collaboration with other institutions working to improve the survival rates of pancreatic cancer."

Dianthus Therapeutics Appoints Adam Veness, Esq., as General Counsel

Retrieved on: 
Tuesday, June 20, 2023
Intellectual property, Therapy, Senior, General counsel, Veness, Science, Tulane University, Boston University School of Law, Philosophy, Acquisition, Patient, Autoimmune disease, Executive Committee, Acceleron Pharma, Growth, Merck, Dianthus, Popular Executive Committee of Valencia, Acceleron, Management

NEW YORK and WALTHAM, Mass., June 20, 2023 /PRNewswire/ -- Dianthus Therapeutics, a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced the appointment of Adam Veness, Esq., as General Counsel. Joining Dianthus most recently from Cyteir Therapeutics, Veness spent much of his career as Senior Vice President, General Counsel and Secretary at Acceleron Pharma Inc. prior to the acquisition by Merck in November 2021. During his tenure at Acceleron, Veness gained experience in roles of increasing responsibility where he served on the Executive Committee responsible for company strategy, and he led all aspects of global legal and compliance, including capital markets and SEC reporting obligations, corporate governance, contracts, intellectual property, employment matters, and data privacy.

Key Points: 
  • Joining Dianthus most recently from Cyteir Therapeutics, Veness spent much of his career as Senior Vice President, General Counsel and Secretary at Acceleron Pharma Inc. prior to the acquisition by Merck in November 2021.
  • "We are excited to welcome Adam to the Dianthus team at such a pivotal time for the company," said Marino Garcia, President and Chief Executive Officer of Dianthus Therapeutics.
  • I am looking forward to working with Adam and to his contributions as we continue to build an exciting biotech company."
  • "I am thrilled to join Dianthus as the company embarks on this exciting chapter of growth," said Adam Veness, Esq., General Counsel of Dianthus Therapeutics.

Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 8, 2023
CMC, Therapy, Senior, IND, Acquisition, Merck, Investment, Chemistry, D, Safety, Patient, Clinical trial, Protein, TED, Webcast, Food, Annual Meetings of the International Monetary Fund and the World Bank Group, Acceleron Pharma, Corporate Affairs, FDA, Pharmaceutical industry, Vaccine, Nursing, Management, Viridian, Research

WALTHAM, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Initial results from the proof-of-concept study of VRDN-001 in patients with chronic TED are expected in the second quarter of 2023.
  • R&D Expenses: Research and development expenses were $39.3 million during the fourth quarter of 2022, compared with $22.4 million for the same period last year.
  • G&A Expenses: General and administrative expenses were $9.9 million during the fourth quarter of 2022, compared with $6.9 million for the same period last year.
  • The Company will host a webcast and conference call to discuss its fourth quarter and full year 2022 financial results today, Wednesday, March 8 at 8:00 a.m.

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

Retrieved on: 
Wednesday, March 8, 2023
Epilepsy, Science, Amgen, MBA, Fibrosis, Growth, Jan Vansina, Seagen, Marketing, Acquisition, Novartis, Commercial, Therapy, Jazz Pharmaceuticals, San Diego State University, GW Pharmaceuticals, ASGE, Acceleron Pharma, SAN, Executive, University, Madison, Chief commercial officer, Journal of Pharmacy and Pharmacology, Ironwood Pharmaceuticals, Pharmacology, Ironwood, Pepperdine University, Pharmaceutical industry, Management, Pharmacy

SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointments of Darren Cline and Thomas McCourt to its Board of Directors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointments of Darren Cline and Thomas McCourt to its Board of Directors.
  • "I am pleased to welcome Darren and Thomas whose extensive commercial and operational expertise will be crucial as we progress toward late-stage clinical development,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics.
  • Mr. Cline currently serves as Chief Executive Officer and President of Epygenix Therapeutics, a clinical stage company developing therapies for rare epilepsies.
  • Mr. Cline currently serves on the board of directors of Pyxis Oncology.

Combined Therapeutics Expands Board of Directors with Appointments of Biopharma Industry Veterans Paul Wotton, Robert Ruffolo and Kevin F. McLaughlin

Retrieved on: 
Wednesday, March 8, 2023
Obsidian, TIL, Pharmacology, MBA, Research, Astellas Pharma, Heart, Therapy, University, Acquisition, Biotechnology, Babson College, Growth, Accounting, Clinical trial, MPH, Discoverer, Infection, Drug discovery, Pharmacy, Messenger, GSK, Robert Paul, Wyeth, CTX, Melanoma, Astellas Institute for Regenerative Medicine, Acceleron Pharma, Carvedilol, GSK plc, Ohio State University, Merck, Combined, University College London, Book, Overalls, Pharmaceutical industry, Vericel, Northeastern University, Doctor of Philosophy

"We are finalizing our financing round and putting in place the infrastructure to advance our mRNA vaccines and therapeutics into clinical development.

Key Points: 
  • "We are finalizing our financing round and putting in place the infrastructure to advance our mRNA vaccines and therapeutics into clinical development.
  • Dr. Wotton is a serial entrepreneur and inventor with more than 30 years of experience in the biotech and pharma industries.
  • He currently serves on the boards of Vericel, Cynata Therapeutics and Kytopen, and is a co-founder and director of Avenge Bio.
  • Mr. McLaughlin is a finance and management executive with more than 40 years of experience in the biopharma and high tech industries.

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Retrieved on: 
Monday, February 6, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Thalassemia, Genzyme, Gongshi, Rock, Patient, Business, Senior, Sociology, New York University Stern School of Business, Marketing, SMA, Acceleron Pharma, Syndrome, SAPPHIRE, Fine chemical, Pfizer, Economics, Sanofi, Boston College

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Tracey M. Sacco as Chief Commercial Officer.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Tracey M. Sacco as Chief Commercial Officer.
  • Ms. Sacco brings extensive biopharmaceutical industry experience, including product launch and global commercial strategy.
  • At Scholar Rock, she will build and lead all commercial functions, including sales, marketing, market access, and commercial operations.
  • To this end, we are thrilled to welcome Tracey to Scholar Rock’s executive team and leverage her depth of commercial experience as the company’s Chief Commercial Officer,” said Dr. Jay Backstrom, M.D., M.P.H., President & Chief Executive Officer of Scholar Rock.

Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer

Retrieved on: 
Wednesday, December 21, 2022
City of London Finance Committee, Investigational New Drug, Biotechnology, Food, Pulmonary hypertension, Therapy, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Merck, United Therapeutics, GSK, Acceleron Pharma, University, FDA, American Board of Nuclear Medicine, Committee on Finance, Acceleron, PAH, Pharmaceutical industry, Genentech

DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions, today announced the appointment of Lisa Yañez as chief executive officer, effective January 1, 2023. As part of a planned leadership transition, Steve Thornton will retire as CEO at the end of the year but remain on the Board of Directors and assume the Chairmanship of the Finance Committee.

Key Points: 
  • DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions, today announced the appointment of Lisa Yañez as chief executive officer, effective January 1, 2023.
  • Ms. Yañez has more than 25 years of leadership experience at leading pharmaceutical and biotechnology companies, including Merck, Genentech, GSK, and most recently, United Therapeutics and Acceleron Pharma.
  • At United Therapeutics, Ms. Yañez led the multi-billion-dollar PAH franchise that includes five of the fifteen currently FDA-approved therapies for PAH.
  • “I look forward to continuing to work closely with her and her team at Aerami Therapeutics as they further develop AER-901 to address high unmet need for new therapeutic options.”

Mnemo Therapeutics Appoints Christine Foster, Ph.D. and Co-Founder Sebastian Amigorene, Ph.D. to Key Leadership Roles

Retrieved on: 
Wednesday, November 30, 2022
Growth, GlaxoSmithKline, SUV39H1, Science, Laboratory, Ionis Pharmaceuticals, Intellia Therapeutics, University, Pharmacology, Multimedia, Responsibility, Therapy, Biotechnology, Degenerative disease, Sebastian Amigorena, Neuroscience, Senior, Acceleron Pharma, Foster, Brandeis University, Regeneron Pharmaceuticals, Teva Pharmaceuticals, Cancer, Research, Memory, Cell biology, CNRS, Immunotherapy, University of Massachusetts Medical School, Mnemos EP, Management, Pharmaceutical industry, Novartis, Princeton University, Immunology, Pfizer

Mnemo also announced the appointment of Scientific Co-Founder Sebastian Amigorena, Ph.D. as Senior Vice President, Immunology.

Key Points: 
  • Mnemo also announced the appointment of Scientific Co-Founder Sebastian Amigorena, Ph.D. as Senior Vice President, Immunology.
  • "Christine brings a stellar history building meaningful value for biopharmaceutical companies by guiding business development and establishing strategic collaborations," said Mnemo Chief Executive Officer Robert LaCaze.
  • "I am thrilled to contribute to the science and innovation taking place at Mnemo Therapeutics," Foster said.
  • To learn more, visit https://mnemo-tx.com and follow Mnemo Therapeutics on Twitter (@MnemoTx) and LinkedIn.